Share on facebook
Share on twitter
Share on linkedin

December 3, 2014: Plasma Gelsolin Patent for Therapeutic Use in Renal Failure Granted in Europe

Patent Covers Therapeutic Uses of Plasma Gelsolin in Renal Failure

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December 3, 2014) BioAegis Therapeutics announces that its portfolio of patents has been expanded with the granting of a second European Patent for plasma gelsolin. Claims in this patent are directed to the treatment of renal failure.